Amarin/AMRN

$0.88

-4.03%
-
1D1W1MYTD1YMAX

About Amarin

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Ticker

AMRN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Patrick Holt

Employees

275

Headquarters

Dublin, Ireland

Amarin Metrics

BasicAdvanced
$377.24M
Market cap
-
P/E ratio
-$0.15
EPS
1.97
Beta
-
Dividend rate
$377.24M
1.96994
$1.49
$0.65
1.81M
2.796
1.799
-6.88%
-10.3%
-9.86%
1.229
0.68
0.708
59.222
-16.87%
45.4%
-20.64%

What the Analysts think about Amarin

Analyst Ratings

Majority rating from 5 analysts.
Hold

Price Targets

Average projection from 3 analysts.
22.73% upside
High $1.25
Low $1.00
$0.88
Current price
$1.08
Average price target

Amarin Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-7.63% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$74.7M
13.18%
Net income
$-5.7M
-70.47%
Profit margin
-7.63%
-73.91%

Amarin Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 66.67%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.04
-$0.04
-$0.05
-$0.01
-
Expected
-$0.03
-$0.04
-$0.05
-$0.03
-$0.03
Surprise
33.33%
14.29%
11.11%
-66.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Amarin stock?

Amarin (AMRN) has a market cap of $377.24M as of April 18, 2024.

What is the P/E ratio for Amarin stock?

The price to earnings (P/E) ratio for Amarin (AMRN) stock is 0 as of April 18, 2024.

Does Amarin stock pay dividends?

No, Amarin (AMRN) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Amarin dividend payment date?

Amarin (AMRN) stock does not pay dividends to its shareholders.

What is the beta indicator for Amarin?

Amarin (AMRN) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Amarin stock price target?

The target price for Amarin (AMRN) stock is $1.08, which is 22.73% above the current price of $0.88. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Amarin stock

Buy or sell Amarin stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing